

S 1269

INSULIN Act of 2023

Congress: 118 (2023–2025, Ended)

Chamber: Senate

Policy Area: Health

Introduced: Apr 25, 2023

Current Status: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Latest Action: Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Apr 25, 2023)

Official Text: <https://www.congress.gov/bill/118th-congress/senate-bill/1269>

Sponsor

Name: Sen. Shaheen, Jeanne [D-NH]

Party: Democratic • **State:** NH • **Chamber:** Senate

Cosponsors (13 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Collins, Susan M. [R-ME]	R · ME		Apr 25, 2023
Sen. Britt, Katie Boyd [R-AL]	R · AL		Jun 22, 2023
Sen. Stabenow, Debbie [D-MI]	D · MI		Jun 22, 2023
Sen. Tester, Jon [D-MT]	D · MT		Jun 22, 2023
Sen. Tuberville, Tommy [R-AL]	R · AL		Jun 22, 2023
Sen. Kelly, Mark [D-AZ]	D · AZ		Sep 19, 2023
Sen. Wicker, Roger F. [R-MS]	R · MS		Sep 19, 2023
Sen. Murkowski, Lisa [R-AK]	R · AK		Oct 4, 2023
Sen. Rosen, Jacky [D-NV]	D · NV		Oct 4, 2023
Sen. Braun, Mike [R-IN]	R · IN		Nov 2, 2023
Sen. King, Angus S., Jr. [I-ME]	I · ME		Nov 2, 2023
Sen. Baldwin, Tammy [D-WI]	D · WI		Nov 9, 2023
Sen. Grassley, Chuck [R-IA]	R · IA		Nov 9, 2023

Committee Activity

Committee	Chamber	Activity	Date
Health, Education, Labor, and Pensions Committee	Senate	Referred To	Apr 25, 2023

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
118 HR 5372	Related bill	Dec 6, 2023: Ordered to be Reported (Amended) by the Yeas and Nays: 48 - 0.
118 S 1067	Related bill	Jun 22, 2023: Placed on Senate Legislative Calendar under General Orders. Calendar No. 107.

Summary (as of Apr 25, 2023)

Improving Needed Safeguards for Users of Lifesaving Insulin Now Act of 2023 or the INSULIN Act of 2023

This bill limits cost-sharing for insulin under private health insurance and revises the requirements for approval and cost-sharing of generic drugs and biosimilar products.

Specifically, the bill caps cost-sharing under private health insurance for a month's supply of selected insulin products at \$35 or 25% of a plan's negotiated price (after any price concessions), whichever is less, beginning in 2025.

The bill also requires pharmacy benefit managers (PBMs) to remit to the group health plan 100% of the fees, alternative discounts, and all other remuneration received from a drug manufacturer.

Additionally, the bill modifies the Food and Drug Administration's (FDA) procedures for determining whether a petition to delay the approval of a generic drug was made with the primary purpose of delaying the application and provides for the referral of such petitions to the Federal Trade Commission. The bill also authorizes the FDA to expedite the development and review of applications for products designated as a competitive biosimilar therapy.

Finally, the bill permits prescription drug plan sponsors under Medicare Part D to make certain mid-year changes to the cost-sharing tier of a reference biological product if the sponsor also adds the respective biosimilar product to the same or a lower cost-sharing tier as the reference biological product immediately prior to the change.

Actions Timeline

- **Apr 25, 2023:** Introduced in Senate
- **Apr 25, 2023:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions.